As Reported was BioCorRx’s largest revenue line in fiscal 2025, bringing in $948.36K of $740.96K (128%).
| Revision of Prior Period | FY 2025 |
|---|---|
| As Reported | $948.36K |
| As Revised | $213.91K |
| Revision | -$421.31K |
| Total | $740.96K |
BioCorRx brought in $740.96K from its three revenue lines in fiscal 2025, the year ended September 30, 2025. As Reported was the largest at $948.36K (128.0%), ahead of As Revised at $213.91K (28.9%).
The total is net of Revision, which took $421.31K off revenue in fiscal 2025.
BioCorRx (BICX) reports its revenue by revision of prior period. In fiscal 2025, As Reported was its largest revenue line, bringing in $948.36K (128.0% of the total), followed by As Revised at $213.91K (28.9%).
As Reported was BioCorRx's largest revenue line in fiscal 2025, bringing in $948.36K, or 128.0% of the $740.96K total across its three revenue lines.
Every figure comes from BioCorRx's annual financial filings, as reported. Each line keeps the name BioCorRx gives it, and years follow its fiscal calendar.
BioCorRx's revenue by revision of prior period goes back to fiscal 2025, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.